Navigation Links
Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference
Date:7/22/2009

DALLAS, July 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, will present at the Jessup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am EDT. The presentation will occur live and will be held at the Waldorf Astoria Boca Beach Club in Boca Raton, Florida.

"We are pleased to have the opportunity to present Access Pharmaceuticals to the large group of institutional and retail investors that attend Jessup's annual growth stock conference," stated Jeffrey B. Davis, Access' President & CEO. "The conference provides a forum for Access to highlight in many product programs, and specifically the very significant and positive initial results and feedback from the commercial launch of MuGard, our FDA approved treatment for oral mucositis. Initial clinical feedback and experience exceeds our expectations."

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere/Anytime Access to Crucial Patient Information
2. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
3. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
4. Over 25,000 Pharmacists and Technicians Access PTCB Funded Web-Based Continuing Education Programs
5. National Hospice and Palliative Care Organizations Caring Connections and Google Health Offer New Way to Access Advance Directives Online
6. Access MediQuip Names Tim Hargarten Chief Executive Officer
7. Critical Access Hospital Consolidator Seeks Cost-Management Solutions with Broadlane
8. Better Business Bureau Selects Language Line Services for New Language Access Program
9. Cancer Roadmaps Chooses Tableau Software for Consumer Access to Online, Interactive Dashboards for Cancer Patients
10. TrinityCare Senior Living, Inc. Information to be Available Through Standard & Poors Market Access Program
11. Pennsylvania Governor Rendell Ceremonially Signs Four Health Care Bills That Will Reduce Costs, Improve Access and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... to share this important news! AHCC and the Home Health and Hospice ICD-10 ... CMS' designee for official ICD coding guidance and clarifications, to address concerns over ...
(Date:2/8/2016)... ... ... The schedule is now online for the largest and most ... being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give the ... chronic illness in children. , Very recent articles have cited 1 child in 20 ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Dynatronics Corporation (NASDAQ: ... medical devices and rehabilitation equipment for the physical ... Denver Broncos, football team for winning the 2016 ... , Chairman and Chief Executive Officer.  "The Broncos ... look forward to enhancing their athletic achievements with ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
Breaking Medicine Technology: